IRIDEX®
GLAUCOMA

A non-incisional treatment runway for glaucoma

Iridex provides an array of established, laser procedures
that expand ways to manage, preserve, and prolong vision.

Glaucoma Treatment Redefined

Glaucoma care has shifted from a 10- to 12-year treatment plan to a 30-year (or more) treatment plan. In response to this paradigm shift, non-incisional laser therapy and minimally invasive glaucoma surgeries (MIGS) have become viable, necessary options for clinicians to postpone the need for invasive surgery in mild to moderate glaucoma patients. Due to the extended lifespan of glaucoma patients, any treatment prescribed in the early stages of glaucoma must minimize tissue damage so that future treatment options are not negated.

Iridex has redefined the glaucoma treatment paradigm with a versatile range of non-incisional, laser-based therapies: **MicroPulse® Laser Trabeculoplasty, MicroPulse® Transscleral Laser Therapy, and Continuous-Wave Transscleral Cyclophotocoagulation**. These therapies provide physicians safe, effective, and practical treatment options for a variety of glaucoma types and severity, to significantly reduce intraocular pressure (IOP)[1-6] and slow the progression of vision loss. Iridex products are sold in the United States and Germany through a direct sales force and in more than 80 additional countries through a network of distributors.



Now there is a non-incisional, safe, and effective continuum of care available to glaucoma patients in over 80 countries

MicroPulse® Technology

Only from Iridex. Since 1994.

Iridex' patented MicroPulse technology chops a continuous-wave laser beam into an envelope of repetitive short "ON" pulses separated by longer "OFF" periods. The OFF periods allow heat to dissipate and reduce thermal buildup within the tissue, which minimizes collateral tissue damage.

MicroPulse is a laser delivery modality that adds fine control of thermal elevation. In conventional photocoagulation, the temperature rise for an intended intraoperative endpoint is controlled by adjusting the power and the exposure duration of the continuous-wave (CW) laser emission.

MicroPulse Technology can be found in multiple glaucoma clinical applications including MicroPulse Laser Trabeculoplasty and MicroPulse Transscleral Laser Therapy.



Represents a 31.3% duty cycle used in MicroPulse TLT

MicroPulse® Laser Trabeculoplasty

A first-line treatment for glaucoma patients

This safe and durable therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven't seen significant effects from medications. MicroPulse Laser Trabeculoplasty (MLT) provides surgeons with an easy to perform, safe and effective treatment option prior to, or in conjunction with, topical medication.

MLT affords long-term durability after a single treatment, or with repeat treatments, to enhance or extend IOP-lowering effects. MLT may improve patient compliance by reducing or eliminating their medication burden. Patients tolerate treatment well with minimal to no downtime. The Iridex laser consoles used for MLT, the IQ 532® Laser and IQ 577® Laser, are versatile and ideal for comprehensive practices whose physicians provide medical retina services in addition to glaucoma care.

Therapy highlights

- ≥20% reduction for up to 12 months[7, 8]
- Less likelihood of an IOP spike than other approaches to laser trabeculoplasty[8, 9]
- Can be performed in about 5-10 minutes in the office, hospital, or ASC
- Well tolerated by patients with no post-treatment lifestyle restrictions
- Covered under CPT 65855 in the United States

Learn More

"**MicroPulse Laser Trabeculoplasty** is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven't seen significant effects from medications.

IKE AHMED, MD, FRCSC
University of Toronto
Toronto, Canada



MicroPulse Laser Trabeculoplasty
Meshwork remains intact without signs of tissue damage, while the treatment is still as effective as Argon Laser Trabeculoplasty (ALT) and Selective Laser Trabeculoplasty (SLT)[10]



Argon Laser Trabeculoplasty
Continuous-wave laser exposures can cause high thermal rise resulting in tissue damage[10]

MLT vs SLT vs ALT

	MLT	SLT	ALT
Wavelength	532 nm, 577 nm	532 nm	488/514 nm, 532 nm
Mechanism	Thermally effects - not destroys - pigmented TM cells	Selective destruction of pigmented TM cells without thermal or collateral damage	Shrinkage of TM with adjacent stretching
Repeatable	Yes	Yes	No
Treatment Endpoint	No visible tissue reaction	Small bubbles	Blanching (mild) to bubbles (intense)
Post op Inflammation	Minimal to none	Yes	Yes
Spot Size	300 µm	400 µm	50 µm



Candidates for MLT include patients who are unable to tolerate medications (e.g., due to allergies) or are unlikely to adhere to prescribed therapeutic regimens, and patients who need adjunctive therapy when monotherapy with topical drops fails.

MicroPulse® Transscleral Laser Therapy

A versatile procedure that can be performed before, in combination with, and after other glaucoma treatments

MicroPulse Transscleral Laser Therapy (TLT) is a cost-effective combination of safety, effectiveness, and repeatability in a non-incisional approach to glaucoma care. MicroPulse TLT is a versatile procedure that can be performed before, in combination with, or after other glaucoma treatments. Since 2015, more than 180,000 patients in over 80 countries have been treated with MicroPulse TLT using the MicroPulse P3® Delivery Device.

Excellent Safety Profile and Efficacy

- Achieves a success rate of 60-80%[11-27] and IOP reduction of 30-45%[11,13,16,19-25,27-29]
- Helps reduce drug burden in eye drops and oral medications[11-14,16-23,28]
- Durability of up to 72 months with three retreatments[30]

Quick and Easy to Perform

- Performed in the OR or office
- Performed in less than 7 minutes
- Requires limited amount of follow-up
- Leaves future treatment options open
- Patient downtime is significantly low
- In most cases, patients can resume their normal activities within 24 hours
- The equipment is intuitive, portable, and easy to setup
- Covered under CPT 66710 in the United States

Learn More

“When treating patients with glaucoma, my number one goal is to prevent blindness, and my number two goal is to prevent incisional glaucoma surgery. **MicroPulse TLT** can help me to achieve both.

NATHAN RADCLIFFE, MD
New York Eye Surgery Center
New York, United States

Scan to watch animation



Strong Clinical Evidence

- 32 peer-reviewed studies have been published on the safety and effectiveness of MicroPulse TLT
- 70 studies show low adverse events
- 70 studies show sustained IOP reduction, some with 30-45% reduction in 60-85% of patients
- 500 eyes in studies demonstrating durability greater than 12 months

Patients to Consider

- Patients with maximum tolerated medical therapy and compliance issues
- Patients with pre-trabeculectomy, stent or filter
- Patients with failed trabeculectomy, stent or filter
- Patients with compromised ocular surface.



The revised MicroPulse P3® Device has a smooth, ergonomic interface to allow clinicians to keep consistent contact with the probe at the limbus. Indications for this device include, but are not limited to, transscleral cyclophotocoagulation for the treatment of primary open-angle glaucoma, closed-angle glaucoma, and refractory glaucoma.

“

MicroPulse TLT has become an essential part of my practice. I use it in some of my most complicated cases, but I also feel comfortable using it on patients in earlier stages of the disease.

ROBERT NOECKER, MD, MBA
Ophthalmic Consultants of Connecticut
Fairfield, CT United States

CW Transscleral Cyclophotocoagulation

Gold standard in the treatment of severe to end-stage glaucoma

Continuous-Wave Transscleral Cyclophotocoagulation (CW-TSCPC) has been the gold standard in the treatment of severe to end-stage glaucoma for over 20 years. In most cases, this highly effective, durable therapy is a patient's last option or is necessary for immediate and major IOP reduction.

Established and Highly Effective

- Performed for over 20 years
- Well tolerated[31-34] with a limited amount of immediate follow-up
- Patient downtime is significantly low
- Can be performed in the OR or office
- Covered under CPT 66710 in the United States

Patients to Consider

- Patients who are not candidates for filtration surgery
- Patients with failed filtration surgery
- Patients with a secondary glaucoma in which failure is a likely outcome of filtration surgery
- Patients who have lost ambulatory-level vision

Learn More

"Recovery with **Continuous-wave TSCPC** is much more rapid, and the postoperative care much less involved, than with someone who has had an incisional glaucoma case in a surgical center.

MAHMOUD A. KHAIMI, MD
Dean McGee Eye Institute
Oklahoma City, OK United States

Quick and Easy to Perform

- Short learning curve and easy to use[35,36]
- The equipment is portable and easy to setup

Available with Transillumination

- Optimized delivery of laser with transillumination to enhance probe placement using the G-Probe Illuminate® Delivery Device





The G-Probe and the G-Probe Illuminate, when used with an Iridex infrared laser, are indicated for transscleral cyclophotocoagulation (TSCPC) of the ciliary processes using continuous-wave.

“

The G-Probe Illuminate for **CW-TSCPC** has really helped me to deliver a targeted treatment with an easy-to-use probe. The visualization of the ciliary body and the surrounding working area is impressive.

STEVEN D. VOLD, MD
Vold Vision
Fayetteville, AR United States

We are committed to supporting glaucoma specialists from around the world and the patients they serve.

“

The revised MicroPulse P3 Device for **MicroPulse TLT** is intuitive and easy to use. The design delivers energy in a much more consistent fashion and allows for very stable contact on the sclera.

BRIAN A. FRANCIS, MD, MS
Doheny Eye Institute, UCLA
Los Angeles, CA United States

“

I was performing **MicroPulse TLT** in refractory glaucoma patients, but as I saw the results and how comfortable the patients were, I started to expand its use, and now I use it for various types of glaucoma cases.

SANDRA FERNANDO SIEMINSKI, MD
Ross Eye Institute
Buffalo, NY United States

“

MicroPulse TLT has become an irreplaceable tool in my daily practice. It has allowed me to better individualize the care of my glaucoma patients, minimizing risks and allowing for clinical success even in challenging scenarios.

TOMAS M. GRIPPO, MD
Grippo Glaucoma Center
Buenos Aires, Argentina

“

It is important to have many choices in managing chronic diseases like glaucoma. Because **MicroPulse TLT** is non-incisional and repeatable, it keeps all other options open.

MAKOTO AIHARA MD, PHD
University of Tokyo
Tokyo, Japan

“

The minimal tissue damage is a major advantage of **MicroPulse TLT** over standard cyclophotocoagulation. The enhancements made to the design of the MicroPulse P3 now allow a smoother movement during treatment.

MARC TOETEBERG-HARMS, MD, FEBO
University of Zurich
Zurich, Switzerland

“

I am impressed with the design of the revised **MicroPulse P3 Probe**. The ergonomics have been significantly improved and the ease of use is quite satisfying. The enhanced design has many features that improve safety, efficacy and patient comfort.

ZIAD KHOUEIR, MD
Beirut Eye Hospital
Beirut, Lebanon

We provide an array of products and therapies that expand ways to manage, preserve and prolong vision.

For MicroPulse® Laser Trabeculoplasty

IQ 532® Laser

A green laser (532 nm) with MicroPulse and continuous-wave treatment modes. Use to perform MLT, and medical retina with an SLA and LIO.

Part Number IQ532-SYSTEM

IQ 577® Laser

A yellow laser (577 nm) with MicroPulse and continuous-wave treatment modes. Use to perform MLT, and medical retina with an SLA and LIO.

Part Number IQ577-SYSTEM

MLT Lens

A laser lens with an integrated reference guide to assist placement of subvisible laser spots during MicroPulse Laser Trabeculoplasty

Part Number 33122

Learn More

Visit iridexglaucoma.com to learn more

For MicroPulse® TLT

Cyclo G6® Laser

An infrared laser (810 nm) with MicroPulse and continuous-wave modes. Can be used in the office or operating room. Use to perform MicroPulse TLT and CW-TSCPC.

Part Number CYCLO-G6-SYSTEM

MicroPulse P3® Device

More than 180,000 patients have been treated since 2015. The enhanced footplate allows it to deliver excellent stability, visualization, coupling, and fit.

Part Number 15522

For CW-TSCPC

G-Probe Illuminate® Device

Includes built-in transillumination, which helps to provide optimal probe placement and excellent therapeutic treatment outcomes.

Part Number 16200

G-Probe® Delivery Device

For more than 20 years, the G-Probe has been used to treat glaucoma. It is the gold standard in the treatment of severe to end-stage glaucoma.

Part Number 15980

Join our webinars and follow us on social media to see cases, opinions, and tips from physicians from around the world










Learn More

Visit iridex.com/webinars to access our webinars

MicroPulse TLT in combination with other glaucoma treatments

Courtney Bovee, MD; Rajen U. Desai, MD, FACS; Sebastian B. Heersink, MD



MicroPulse TLT after incisional glaucoma treatments

Jella An, MD; Analisa Arosemena, MD; Jacob Brubaker, MD; Shan Lin, MD

When to treat glaucoma with MicroPulse TLT and when to treat with CW-TSCPC

Mahmoud A. Khaimi, MD; Richard K. Lee, MD, PhD; Robert Noecker, MD, MBA; Nir Shoham-Hazon, MD

All-laser approach to glaucoma

Ike K. Ahmed, MD; Jella An, MD; Mahmoud A. Khaimi, MD

Experiences in Latin America with MicroPulse® TLT for glaucoma

Tomás M. Grippo, MD; Vanessa Liberato, MD; Vital P. Costa, MD; Francisco Ortega, MD; María F. Delgado, MD

Experiences in Europe with MicroPulse® TLT for glaucoma

Prof. Florent Aptel, MD, PhD; Ronald de Crom, MD; Marc Mackert, MD, FEBO; Marc Töteberg-Harms, MD, FEBO

Specifications and ordering information

Cyclo G6® Laser (810 nm Infrared)

Weight	4.8 kg (10.5 lb)
Dimensions	27 cm x 29.5 cm x 19.7 cm (10.6” W x 11.6” D x 7.8” H)
Connector type	SmartProbe RFID
Electrical	100-240 VAC, 50/60 Hz, <0.8 A
Cooling	Air cooled
Exposure duration	CW-Pulse: 10 ms – 9000 ms in 606 increments and continuous pulse up to 60 seconds
Exposure interval	CW-Pulse: 10 – 3000 ms in 598 increments and One Pulse
MicroPulse duration	MicroPulse: 0.05-1.0 ms in 19 increments
MicroPulse interval	MicroPulse: 1.0-10.0 ms in 90 increments
MicroPulse duty cycle	Continuously adjustable from 0.5%-50%, and preset selections of 5%, 10%, and 15% duty cycles
Aiming beam	Diode laser, 635 nm nominal
Treatment power	50-3000 mW, depending on delivery device
Part number	CYCLO-G6-SYSTEM

MicroPulse P3®

- Part number 15522
- Comes in box of 6
- Single-use device

G-Probe®

- Part number 15980
- Comes in box of 6
- Single-use device

G-Probe Illuminate®

- Part number 16200
- Comes in box of 6
- Single-use device

MLT Lens

- Part number 33122
- Compatible with IQ 532 Laser and IQ 577 Laser

IQ 532® Laser (532 nm Green)

Weight	9.0 kg (19.2 lb)
Dimensions	30.5 cm x 35.6 cm x 21.4 cm (12 in W x 14 in D x 8.5 H)
Connector type	RFID	Resistor
Electrical	100–240 VAC, 50/60 Hz
Cooling	Air/TEC cooled
Exposure duration	CW-Pulse™: 10 ms – 3000 ms or CW to 60 seconds
Exposure interval	CW-Pulse: 10 ms – 3000 ms or single pulse
MicroPulse duration	MicroPulse: 0.05–1.00 ms
MicroPulse interval	MicroPulse: 1.00–10.00 ms
Aiming laser	Diode laser, 635 nm nominal
Delivery device power output	TxCell, SLA, LIO, and EndoProbe: 0–2000 mW; OtoProbe: 0–2500 mW
Part number	IQ532-SYSTEM

IQ 577® Laser (577 nm Yellow)

Weight	9.0 kg (19.2 lb)
Dimensions	30.5 cm x 35.6 cm x 21.4 cm (12 in W x 14 in D x 8.5 H)
Connector type	RFID	Resistor
Electrical	100–240 VAC, 50/60 Hz
Cooling	Air/TEC cooled
Exposure duration	CW-Pulse™: 10 ms – 3000 ms or CW to 60 seconds
Exposure interval	CW-Pulse: 10 ms – 3000 ms or single pulse
MicroPulse duration	MicroPulse: 0.05–1.00 ms
MicroPulse interval	MicroPulse: 1.00–10.00 ms
Aiming laser	Diode laser, 635 nm nominal
Delivery device power output	TxCell, SLA, LIO, and EndoProbe: 0–2000 mW
Part number	IQ577-SYSTEM

To order Iridex products, speak with your local sales representative or distributor, or email us at glaucoma@iridex.com

References

1. Hong Y, et al. Int J Ophthalmol. 2019
2. Varikuti VNV, et al. J Glaucoma. 2019
3. Al Habash A, et al. Clinical Ophthalmology. 2019
4. Preda MA, et al. Lasers Med Sci. 2020
5. Tekeli O, et al. Eur J Ophthalmol. 2020
6. Duerr ERH, et al. Ophthalmology Glaucoma. 2018
7. Fea AM, et al. Clin Ophthalmol. 2008
8. Abramowitz B, et al. Clin Ophthalmol. 2018
9. Thomas C, et al. Invest Ophthalmol Vis Sci. 2019
10. Fudemberg SJ, et al. Invest Ophthalmol Vis Sci. 2008
11. Zaarour K, et al. J Glaucoma 2019
12. Subramaniam K, et al. Cornea 2019
13. Nguyen AT, et al. Eur J Ophthalmol 2019
14. Barac R, et a. Romanian J Ophthalmol 2018
15. Sanchez FG, et al. Arch Soc Esp Oftalmol 2018
16. Lee JH, et al. J Glaucoma 2017
17. Sarrafpour S, et al. Ophthalmology Glaucoma 2019
18. Awoyesuku EA, et al. JAMMR 2019
19. Abdelrahman AM, et al. J Glaucoma 2018
20. Aquino MC, et al. Clin Exp Ophthalmol 2015
21. Jammal AA, et al. Arq Bras Oftalmol 2019
22. Tan A, et al. Clin Experiment Ophthalmol 2010
23. Williams AL, et al. J Glaucoma 2018
24. Varikuti VNV, et al. J Glaucoma 2019
25. Souissi S, et al. Eur J Ophthalmol 2019
26. Magacho L, et al. Lasers Med Sci 2019
27. Magacho L, et al. J Glaucoma 2019
28. Yelenskiy A, et al. J Glaucoma 2018
29. Nguyen AT, et al. Eur J Ophthalmol. 2020
30. Aquino MC, et al. European Glaucoma Society 2016
31. Kosoko O, et al. Ophthalmology 1996
32. Hawkins TA, et al. Arch Ophthalmol 1993
33. Bloom PA, et al. Ophthalmology 1997
34. Brancato R, et al. Eur J Ophthalmol 1995
35. Pucci V, et al. Ophthalmologica 2003
36. Spencer AF, et al. Br J Ophthalmol 1999

IRIDEX®

Learn More

EC REP **Emergo Europe**
Prinsessegracht 20 • 2514 AP The Hague • The Netherlands

Iridex • 1212 Terra Bella Avenue • Mountain View, CA 94043 • U.S.A.
800.388.4747 (U.S.A. only) • 1.650.940.4700 • glaucoma@iridex.com • iridexglaucoma.com

88288 Rev. A 05.2022

℞

CE 2797

VISIBLE AND INVISIBLE LASER RADIATION
AVOID EYE OR SKIN EXPOSURE TO
DIRECT OR SCATTERED RADIATION
CLASS 4 LASER PRODUCT
CLASS 2 LASER PRODUCT
(IEC 60825-1:2014)

λ = 810 nm P_o = 3 W
λ = 635 nm P_o = 1 mW